Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.51 |
| ▸ | TLR2 | O60603 | 9/20 | 0.51 |
| ▸ | VCP | P55072 | 2/20 | 0.47 |
| ▸ | FBP1 | P09467 | 6/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11772249 | 0.82 | FBP1 (0.56) | VCPFBP1ABL1EGFRABL2 | |
| SCHEMBL676041 | 0.81 | FBP1 (0.47) | TLR4TLR2VCPFBP1ABL1 | |
| SCHEMBL678791 | 0.81 | FBP1 (0.47) | TLR4TLR2VCPFBP1ABL1 | |
| SCHEMBL678622 | 0.79 | KIF11 (0.61) | CHEK1MAPT | |
| SCHEMBL18388850 | 0.77 | PARP1 (0.58) | CHEK1EGFRMAPT | |
| SCHEMBL7983662 | 0.74 | FBP1 (0.44) | TLR4TLR2VCPFBP1EGFR | |
| SCHEMBL8687739 | 0.69 | CNR1 (0.53) | TLR4TLR2VCPFBP1MAPT | |
| SCHEMBL8133534 | 0.69 | KMT2A (0.60) | TLR4TLR2VCPCHEK1MAPT | |
| SCHEMBL8133535 | 0.69 | KMT2A (0.60) | TLR4TLR2VCPCHEK1MAPT | |
| SCHEMBL21069968 | 0.69 | MEN1 (0.55) | MAPTIDO1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | TLR4 2984/4885TLR2 3164/4885VCP 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.